Lori Gautreaux, MD
Internal Medicine · Lafayette, LANPI 1942576855
Payments from drug & device makers
Across 215 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$702
- GSK$309
- Lilly USA, LLC$265
- Sumitomo Pharma America, Inc.$247
- Novo Nordisk$230
- AstraZeneca$207
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,350100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $702 |
| GSK | 19 | $309 |
| Lilly USA, LLC | 18 | $265 |
| Sumitomo Pharma America, Inc. | 19 | $247 |
| Novo Nordisk | 15 | $230 |
| AstraZeneca | 11 | $207 |
| Bayer | 6 | $107 |
| Esperion Therapeutics, Inc. | 6 | $104 |
| Amgen | 7 | $97 |
| Boehringer Ingelheim | 7 | $96 |
| Kowa Pharmaceuticals America, Inc. | 5 | $82 |
| Abbott | 4 | $81 |
| Ardelyx, Inc. | 4 | $80 |
| Exact Sciences | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Pfizer | 4 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $66 |
| Amarin Pharma, Inc. | 4 | $61 |
| Arbor Pharmaceuticals, Inc. | 5 | $59 |
| Ironwood Pharmaceuticals, Inc | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Harmony Biosciences LLC | 2 | $33 |
| Corcept Therapeutics | 1 | $29 |
| Dexcom, Inc. | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Novartis | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 2 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Smith+Nephew | 1 | $13 |
| Nevro Corp. | 1 | $13 |
How this compares
$3,365 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 201 | $270,836 |
| MounjaroTirzepatide | 115 | $125,832 |
| TrulicityDulaglutide | 83 | $124,273 |
| JardianceEmpagliflozin | 61 | $77,119 |
| LinzessLinaclotide | 88 | $76,132 |
| FarxigaDapagliflozin Propanediol | 87 | $73,851 |
| JanuviaSitagliptin Phosphate | 76 | $71,050 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $48,359 |
| EliquisApixaban | 40 | $34,770 |
| VraylarCariprazine Hcl | 21 | $30,536 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $29,866 |
| GemtesaVibegron | 23 | $25,099 |
| XareltoRivaroxaban | 38 | $22,108 |
| EntrestoSacubitril/Valsartan | 11 | $18,661 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $18,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $230 | $270,836201 claims |
| Lilly USA, LLCMounjaro, Trulicity | $265 | $250,105198 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $96 | $123,925120 claims |
| AbbVieLinzess, Vraylar | $702 | $106,668109 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $207 | $101,491138 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $309 | $62,86782 claims |
| PfizerEliquis | $68 | $34,77040 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $247 | $25,09923 claims |
| NovartisEntresto | $15 | $18,66111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $71 | $12,45123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Lafayette
- Bryan LebeanLafayette$53K
- Nethuja SalagundlaLafayette$32K
- Himani Reddy ManthenaLafayette$28K
- Hector RoblesLafayette$19K
- Brad BroussardLafayette$17K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.